Results for tag: "Immuno Oncology Clinical Trials"

Immuno Oncology (IO) is a rapidly growing field of oncology drug development that focuses on harnessing the body's own immune system to fight cancer. IO drugs are designed to target and block specific pathways that cancer cells use to evade the immune system. These drugs can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. IO clinical trials are designed to evaluate the safety and efficacy of these drugs in treating various types of cancer. IO clinical trials are conducted in phases, with each phase designed to assess different aspects of the drug's safety and efficacy. Phase I trials are typically conducted in small groups of patients to assess the drug's safety and tolerability. Phase II trials are larger and are designed to assess the drug's efficacy in treating a specific type of cancer. Phase III trials are the largest and are designed to compare the drug's efficacy to existing treatments. Some of the major companies in the IO clinical trials market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Novartis. These companies are actively involved in the development and testing of IO drugs for the treatment of various types of cancer. Show Less Read more